Myelodysplastic Syndromes and Myeloproliferative Neoplasms

Expert faculty review and share their insights and perspectives on key findings in MDS and MPNs presented at the 2022 ASH Annual Meeting.

Share

Program Content

Activities

  • Hematology 2022: MDS and MPNs
    Key Studies in Myelodysplastic Syndromes and Myeloproliferative Neoplasms: Independent Conference Coverage of ASH 2022
    Conference Coverage
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 16, 2023

    Expires: March 15, 2024

Activities

MOMENTUM Update
MOMENTUM: Updated Analysis of Momelotinib vs Danazol in Symptomatic, Anemic Patients With Myelofibrosis Previously Treated With a JAKi
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2022

Expires: December 11, 2023

Ruxolitinib in CMML
Phase II Expansion Study of Ruxolitinib for the Treatment of Symptomatic CMML
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2022

Expires: December 12, 2023

STIMULUS-MDS1
STIMULUS-MDS1: Randomized, Placebo-Controlled Phase II Trial of Sabatolimab, a TIM-3 Inhibitor, Plus HMA in Higher-Risk MDS
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2022

Expires: December 12, 2023

Add-on Parsaclisib in MF
Phase II Study of Parsaclisib Add-on Therapy in Patients With Myelofibrosis and Suboptimal Response to Ruxolitinib: Final Results
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2022

Expires: December 13, 2023

Sintra-REV Final Results
Sintra-REV: Final Results of Low-Dose Lenalidomide vs Placebo in Non‒Transfusion Dependent Patients With Low-Risk del(5q) MDS
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2022

Expires: December 14, 2023

REFINE: Navitoclax + Ruxolitinib for MF
REFINE Cohort 3: Combination Therapy With Navitoclax, a Novel BCL-2 Family Inhibitor, and Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2022

Expires: December 14, 2023

MDS Classification Systems Validation
Retrospective Analysis for Validation of 2022 WHO and ICC Classification Systems for Patients With Myelodysplastic Syndromes
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2022

Expires: December 15, 2023

Ropeginterferon Alfa-2b in Early MF
Phase II Study of Ropeginterferon Alfa-2b for Patients With Dynamic International Prognostic Scoring System Low/Intermediate-1–Risk, Prefibrotic Primary MF
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2022

Expires: December 16, 2023

Selinexor + Ruxolitinib for MF
Phase I Trial of Selinexor With Ruxolitinib in Previously Untreated Myelofibrosis
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2022

Expires: December 16, 2023

Ruxolitinib in PV and ET
JAK2 V617F Molecular Response to Long-term Ruxolitinib Therapy in Patients With PV and ET
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 19, 2022

Expires: December 18, 2023

Faculty

cover img faculity

Srdan Verstovsek, MD, PhD

Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

cover img faculity

Amer Zeidan, MBBS, MHS

Associate Professor of Medicine (Hematology)
Chief, Division of Hematologic Malignancies
Yale Comprehensive Cancer Center and Smilow Cancer Hospital
New Haven, Connecticut

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen